☆ 4.5 Article

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)

Journal

JOURNAL OF THE NEUROLOGICAL SCIENCES

Volume 412, Issue -, Pages -

Publisher

ELSEVIER

DOI: 10.1016/j.jns.2020.116803

Keywords

-

Categories

Clinical Neurology Neurosciences

Funding

NCATS NIH HHS [UL1 TR001863] Funding Source: Medline

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Clinical Neurology

Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New Developments in Diagnosis and Treatment

Robert Pascuzzi, Cynthia Bodkin

Summary: Myasthenia Gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are the most common disorders involving defective neuromuscular transmission in clinical practice. Patients often experience fatigable weakness and fluctuation in symptoms, regardless of whether the etiology is autoimmune, paraneoplastic, genetic, or toxic. Autoimmune MG is the most prevalent neuromuscular transmission disorder in adults, while LEMS is comparatively rare but requires familiarity with its clinical presentation, diagnosis, and management.

NEUROPSYCHIATRIC DISEASE AND TREATMENT (2022)

Add to Collection

Review Clinical Neurology

Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review

Carly Seligman, Yu-Mei Chang, Jie Luo, Oliver A. Garden

Summary: While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, their use has been linked to immune-related adverse events (irAEs), including myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS). This study aims to provide a comprehensive synthesis of evidence supporting the role of ICIs in the onset of MG and LEMS in patients without prior autoimmune disease. The hypothesis is that ICIs may trigger MG and LEMS in patients with no prior susceptibility to autoimmune disease.

FRONTIERS IN NEUROLOGY (2023)

Add to Collection

Review Clinical Neurology

Neuromuscular junction disorders beyond myasthenia gravis

Shin J. Oh

Summary: Amifampridine has been approved by the FDA for effective symptomatic treatment in LEMS, while MLOS is a newly coined syndrome. LGI1 and CASPR2 antibody tests are recommended for Isaacs syndrome.

CURRENT OPINION IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Autonomic dysfunction detected by skin sympathetic response in Lambert-Eaton myasthenic syndrome: a case report

Jinghong Zhang, Xusheng Huang, Qiang Shi

Summary: This case report presents a patient with Lambert-Eaton myasthenic syndrome (LEMS) and autonomic disorder, providing detailed results of the skin sympathetic response (SSR) test. Due to the significant impact of autonomic dysfunction on clinical management, SSR test is recommended as an effective detection method.

BMC NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patient

Alexandra Duplaine, Camille Prot, Gwendal Le-Masson, Antoine Soulages, Fanny Duval, Caroline Dutriaux, Sorilla Prey

Summary: This study presents a rare case of MG-LE overlap syndrome diagnosed after anti-PD1 immunotherapy for metastatic melanoma, which initially appeared after radiation therapy and relapsed after brain radiation necrosis. The potential role of brain inflammation as a trigger for MG-LE onset is hypothesized. Neuro-muscular junctions disease induced or revealed by checkpoint inhibitors can be challenging and necessitate long-term follow-up.

NEUROLOGICAL SCIENCES (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Long-Standing Lambert-Eaton Myasthenic Syndrome Caused by Undetectable Small-Cell Lung Cancer: Why We Should Follow-Up LEMS

Bo Young Hong, Ho Jung An, Seong Hoon Lim

Summary: Physicians often encounter patients with unexplained muscle weakness and dysphagia. Lambert-Eaton myasthenic syndrome (LEMS) can cause unexplained weakness or dysphagia and is often accompanied by neoplastic conditions. Long-term follow-up is important for diagnosing and managing LEMS.

DIAGNOSTICS (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Lambert-Eaton Myasthenic Syndrome in Lung Cancer

Yongbin Wang, Chuanguo Xu, Yu Wang, Feifei Feng, Hui Wang, Ying Zhang, Xiaojuan Lin, Bin Xu

Summary: The aim of this study was to investigate the clinical and electrical characteristics as well as prognosis in patients with lung cancer and Lambert-Eaton myasthenic syndrome (LEMS). The study found that LEMS usually occurs before lung cancer, and it is more common in men. Most patients experienced nervous system lesions prior to the occurrence of lung cancer.

CONTRAST MEDIA & MOLECULAR IMAGING (2022)

Add to Collection

Article Clinical Neurology

Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE)

Amanda C. Guidon, Srikanth Muppidi, Richard J. Nowak, Jeffrey T. Guptill, Michael K. Hehir, Katherine Ruzhansky, Leeann B. Burton, David Post, Gary Cutter, Robin Conwit, Nicte Mejia, Henry J. Kaminski, James F. Howard

Summary: Telemedicine may be well-suited for myasthenia gravis (MG) due to its specialized care needs, fluctuating muscle weakness, and potential for increased virus exposure during the COVID-19 pandemic. This paper outlines step-by-step guidance on a telemedicine assessment for MG, introducing the MG-CE as a MG-specific, telemedicine physical examination with eight components. Pre-visit preparation, remote patient-reported outcome scales, and visit documentation are also addressed, with identified knowledge gaps for future investigation in telemedicine specific to MG care.

MUSCLE & NERVE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Neuromuscular Active Zone Structure and Function in Healthy and Lambert-Eaton Myasthenic Syndrome States

Scott P. Ginebaugh, Yomna Badawi, Tyler B. Tarr, Stephen D. Meriney

Summary: The mouse neuromuscular junction (NMJ) has been widely used as a model synapse to study neurotransmission. Understanding the relationships within the highly organized active zones (AZs) is crucial for healthy synapses and the pathophysiology of neuromuscular diseases.

BIOMOLECULES (2022)

Add to Collection

Article Clinical Neurology

Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome

Annabel M. Ruiter, Ellen Strijbos, Robert H. P. de Meel, Alexander F. Lipka, Wouter F. Raadsheer, Martijn R. Tannemaat, Jan J. G. M. Verschuuren

Summary: The Dutch-Belgian registry for NMJ disorders is a large and valuable resource providing insights into the disease characteristics and comorbidities of MG and LEMS patients. The reported rates of corticosteroid-related comorbidities and other autoimmune diseases are higher than previously expected, highlighting the importance of early initiation of corticosteroid-sparing treatment. The registry also reveals a high prevalence of patients with unknown antibody status, emphasizing the need for further research and monitoring.

NEUROMUSCULAR DISORDERS (2021)

Add to Collection

Article Medicine, General & Internal

Two Lambert-Eaton Myasthenic Syndrome Patients with Ameliorated Activities of Daily Living Due to Cholinesterase Inhibitors

Hiroshi Yamasaki, Naonobu Futamura, Itaru Funakawa, Nobuo Kohara, Shunsuke Yoshimura, Masakatsu Motomura

Summary: We report two LEMS patients who responded dramatically to cholinesterase inhibitors. Cholinesterase inhibitors were effective in improving gait disturbance and autonomic symptoms in LEMS patients.

INTERNAL MEDICINE (2022)

Add to Collection

Article Clinical Neurology

Lambert-Eaton myasthenic syndrome

Micaela A. Hernandez, Alejandro A. Kohler, Mariano Marrodan, Andrea Lautre, Patricio Brand, Martin Nogues, Fabio Barroso

Summary: This study found that the characteristics of LEMS patients in Argentina are not significantly different, and 70% of patients can improve symptomatically with pyridostigmine. However, the relationship between the DELTA-P score and the risk of small-cell lung carcinoma is not clear.

REVISTA DE NEUROLOGIA (2021)

Add to Collection

Article Clinical Neurology

Impact of the COVID-19 pandemic on patients with myasthenia gravis: A survey of the Myasthenia Gravis Foundation of America MG patient registry

Andres M. De Leon, Inmaculada Aban, Tarrant McPherson, Volkan Granit, Michael Benatar, Gary Cutter, Ikjae Lee

Summary: This study aimed to characterize the behavior of MG patients during the COVID-19 pandemic and identify risk factors associated with COVID-19 infection. The study found that COVID-19 infection rates increased among MG patients during the early pandemic, and MG patients who had face-to-face contact with a COVID-19 infected individual, had more people in the household, and had unstable disease were at higher risk for COVID-19 infection.

MUSCLE & NERVE (2023)

Add to Collection

Article Clinical Neurology

Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic

Dario Ricciardi, Silvia Casagrande, Francesco Iodice, Bianca Orlando, Francesca Trojsi, Giovanni Cirillo, Marinella Clerico, Marco Bozzali, Letizia Leocani, Gianmarco Abbadessa, Giuseppina Miele, Gioacchino Tedeschi, Simona Bonavita, Luigi Lavorgna

Summary: The COVID-19 pandemic has necessitated urgent changes in the healthcare system to ensure continued care for patients with chronic neurological diseases like myasthenia gravis. This analysis explores unresolved issues in managing myasthenic patients, the potential of digital technologies, and proposes an online evaluation protocol based on 4 simple tests to enhance MG management. Telemedicine and digital technology have the potential to aid neurologists in making clinical decisions for MG management, reducing unnecessary in-person consultations and optimizing time and space during the pandemic.

NEUROLOGICAL SCIENCES (2021)

Add to Collection

Review Clinical Neurology

Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review

Cleonisio Leite Rodrigues, Hermany Capistrano de Freitas, Paulo Reges Oliveira Lima, Pedro Helder de Oliveira Junior, Jose Marcelino Aragao Fernandes, Jose Artur Costa D'Almeida, Paulo Ribeiro Nobrega

Summary: This study reports 8 cases of MG exacerbation or myasthenic crisis associated with COVID-19 and discusses prognosis and treatment. The majority of patients were female and the mortality rate was considerably higher.

NEUROLOGICAL SCIENCES (2022)

Add to Collection

Letter Clinical Neurology

Reply to the Letter to the Editor in response to Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal

Andreas Meisel, Fulvio Baggi, Anthony Behin, Amelia Evoli, Anna Kostera-Pruszczyk, Renato Mantegazza, Raul Juntas Morales, Anna Rostedt Punga, Sabrina Sacconi, Michael Schroeter, Jan Verschuuren, Louise Crathorne, Kris Holmes, Maria-Isabel Leite

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Add to Collection

Article Public, Environmental & Occupational Health

Racial and ethnic differences in timing of diagnosis and clinical services received in Duchenne Muscular Dystrophy

Joshua R. Mann, Yanan Zhang, Suzanne McDermott, Yinding Wang, Bo Cai, Kristin M. Conway, Pangaja Paramsothy, Julie Royer, Swamy Venkatesh, James F. Howard, Emma Ciafaloni, MD STARnet

Summary: This study aimed to analyze whether there are racial/ethnic differences in the timing of diagnostic testing and treatments for males with Duchenne Muscular Dystrophy (DMD). The results showed significant delays for five of seven milestones in non-Hispanic Black individuals compared to non-Hispanic White individuals, while the findings for Hispanic individuals were less consistent. Efforts to address barriers to early evaluation and diagnosis for non-Hispanic Black children with DMD may promote more timely initiation of recommended disease monitoring and interventions.

NEUROEPIDEMIOLOGY (2023)

Add to Collection

Article Biology

OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases

Gabriel Sturm, Kalpita R. Karan, Anna S. Monzel, Balaji Santhanam, Tanja Taivassalo, Celine Bris, Sarah A. Ware, Marissa Cross, Atif Towheed, Albert Higgins-Chen, Meagan J. McManus, Andres Cardenas, Jue Lin, Elissa S. Epel, Shamima Rahman, John Vissing, Bruno Grassi, Morgan Levine, Steve Horvath, Ronald G. Haller, Guy Lenaers, Douglas C. Wallace, Marie-Pierre St-Onge, Saeed Tavazoie, Vincent Procaccio, Brett A. Kaufman, Erin L. Seifert, Michio Hirano, Martin Picard

Summary: A meta-analysis of mitochondrial disease patients demonstrates that OxPhos defects contribute to hypermetabolism. Patient-derived fibroblast experiments confirm that mitochondrial OxPhos defects induce cell-autonomous hypermetabolism, which is associated with accelerated telomere shortening and epigenetic aging.

COMMUNICATIONS BIOLOGY (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

Ravulizumab for the treatment of myasthenia gravis

Fiammetta Vanoli, Renato Mantegazza

Summary: Myasthenia gravis (MG) is an autoimmune disorder affecting the neuromuscular junction. Current treatments rely on nonselective immunosuppression, but have significant side effects and some patients are refractory. Ravulizumab, a selective immunosuppressive drug, has shown promising results in a randomized-controlled study (CHAMPION MG).

EXPERT OPINION ON BIOLOGICAL THERAPY (2023)

Add to Collection

Letter Pharmacology & Pharmacy

Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis

Fiammetta Vanoli, Renato Mantegazza

EXPERT OPINION ON PHARMACOTHERAPY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

MiR-146a in ALS: Contribution to Early Peripheral Nerve Degeneration and Relevance as Disease Biomarker

Eleonora Giagnorio, Claudia Malacarne, Paola Cavalcante, Letizia Scandiffio, Marco Cattaneo, Viviana Pensato, Cinzia Gellera, Nilo Riva, Angelo Quattrini, Eleonora Dalla Bella, Giuseppe Lauria, Renato Mantegazza, Silvia Bonanno, Stefania Marcuzzo

Summary: Amyotrophic lateral sclerosis (ALS) is characterized by the loss of upper and lower motor neurons (UMNs, LMNs) and miR-146a dysregulation may contribute to the pathogenesis of ALS. In this study, miR-146a levels were increased in ALS peripheral nerves and decreased in the serum of ALS patients, suggesting its potential as a diagnostic and prognostic biomarker for the disease.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Clinical Neurology

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension

Andreas Meisel, Djillali Annane, Tuan Vu, Renato Mantegazza, Masahisa Katsuno, Rasha Aguzzi, Glen Frick, Laura F. Gault, James Howard Jr

Summary: This study analyzed the interim results of an ongoing open-label extension study to evaluate the long-term treatment effects of ravulizumab in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. The findings showed that ravulizumab demonstrated sustained efficacy and safety in improving the disease condition of patients.

JOURNAL OF NEUROLOGY (2023)

Add to Collection

Article Clinical Neurology

Concordance between patient- and physician-reported Myasthenia Gravis Activities of Daily Living (MG-ADL) scores

Sarah Dewilde, M. F. Janssen, Nafthali H. Tollenaar, Fiammetta Vanoli, Rita Frangiamore, Glenn Phillips, Sandra Paci, Renato Mantegazza, Andreas Meisel, Frauke Stascheit

Summary: This study aims to assess the concordance between self- and physician-reported MG-ADL scores. The results show that patients and neurologists have a concordant assessment of the patient's MG symptoms when using the MG-ADL scale. This evidence supports patient self-administration of the MG-ADL in clinical practice and research.

MUSCLE & NERVE (2023)

Add to Collection

Article Clinical Neurology

Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials

Jeffrey T. Guptill, Michael Benatar, Volkan Granit, Ali A. Habib, James F. Howard, Carolina Barnett-Tapia, Richard J. Nowak, Ikjae Lee, Katherine Ruzhansky, Mazen M. Dimachkie, Gary R. Cutter, Henry J. Kaminski

Summary: The lack of standardization in outcome measures in myasthenia gravis clinical trials has led to confusion and variability in data. A group of experts summarized key outcome measures and made recommendations for improvements. Changes to outcome measure instructions and specific instruments were proposed, with a focus on the Quantitative MG score requiring the most attention. Training materials and revised documents will be made available to study teams.

NEUROLOGY (2023)

Add to Collection

Article Nutrition & Dietetics

Patient-Reported Experiences with a Low-Carbohydrate Ketogenic Diet: An International Survey in Patients with McArdle Disease

Nicoline Lokken, Nicol C. C. Voermans, Linda K. Andersen, Walaa Karazi, Stacey L. L. Reason, Heidi Zweers, Gustav Wilms, Alfredo Santalla, Edward Susanibar, Alejandro Lucia, John Vissing

Summary: The low-carbohydrate ketogenic diet (LCKD) has been increasingly used as a potential treatment option for individuals with McArdle disease. This study aimed to collect patient-reported experiences with a LCKD and found that one-third of the McArdle disease cohort had tried a LCKD. The majority of individuals reported positive effects on core symptoms, while adverse effects were rare and mild to moderate.

NUTRIENTS (2023)

Add to Collection

Article Clinical Neurology

Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis

Gianvito Masi, Minh C. C. Pham, Tabitha Karatz, Sangwook Oh, Aimee S. S. Payne, Richard J. J. Nowak, James F. F. Howard Jr, Jeffrey T. T. Guptill, Vern C. C. Juel, Kevin C. C. O'Connor

Summary: To compare the immunopathology of immune checkpoint inhibitor-induced myasthenia gravis (ICI-MG) and idiopathic MG, the researchers analyzed the AChR autoantibody pathogenic properties. They found that out of three ICI-MG patients with AChR autoantibodies, only one showed complement activation and modulation/blocking potency, similar to idiopathic MG. The other two patients did not exhibit AChR autoantibody-mediated effector functions, questioning the role of these antibodies in the pathology.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization

Nicola Iacomino, Letizia Scandiffio, Fabio Conforti, Erika Salvi, Maria Cristina Tarasco, Federica Bortone, Stefania Marcuzzo, Ornella Simoncini, Francesca Andreetta, Daniela Pistillo, Emanuele Voulaz, Marco Alloisio, Carlo Antozzi, Renato Mantegazza, Tommaso Martino De Pas, Paola Cavalcante

Summary: The thymus plays a role in the development of autoimmunity in myasthenia gravis (MG) patients. Changes in gene expression related to muscle autoantigens, such as AChR α subunit (CHRNA1) and autoimmune regulator (AIRE), as well as tumor-related muscle-like proteins (NEFM, HSP60, RYR1, RYR3, TTN), were observed in MG thymuses with hyperplasia and thymoma. These findings suggest a potential mechanism for the development of MG in thymomas involving altered autoantigen expression and molecular mimicry.

BIOMEDICINES (2023)

Add to Collection

Article Clinical Neurology

Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study

Vera Bril, James F. Howard Jr, Chafic Karam, Jan L. De Bleecker, Hiroyuki Murai, Kimiaki Utsugisawa, Peter Ulrichts, Edward Brauer, Sihui Zhao, Renato Mantegazza, Tuan Vu, ADAPT Study Grp

Summary: Efgartigimod is beneficial in improving muscle function and strength across all muscle groups in patients with gMG by reducing IgG concentration and showing significant improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Add to Collection

Letter Clinical Neurology

Efgartigimod improves triple-negative myasthenia gravis

Rita Frangiamore, Elena Rinaldi, Fiammetta Vanoli, Francesca Andreetta, Renato Mantegazza, Carlo Antozzi

NEUROLOGICAL SCIENCES (2023)

Add to Collection

Correction Clinical Neurology

New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy (vol 143, pg 2696, 2020)

Jorge Alonso-Perez, Lidia Gonzalez-Quereda, Luca Bello, Michela Guglieri, Volker Straub, Pia Gallano, Claudio Semplicini, Elena Pegoraro, Vittoria Zangaro, Andres Nascimento, Carlos Ortez, Giacomo Pietro Comi, Leroy ten Dam, Marianne De Visser, A. J. van der Kooi, Cristina Garrido, Manuela Santos, Ulrike Schara, Andrea Gangfuss, Nicoline Lokken, Jesper Helbo Storgaard, John Vissing, Benedikt Schoser, Gabriele Dekomien, Bjarne Udd, Johanna Palmio, Adele D'Amico, Luisa Politano, Vincenzo Nigro, Claudio Bruno, Chiara Panicucci, Anna Sarkozy, Omar Abdel-Mannan, Alicia Alonso-Jimenez, Kristl G. Claeys, David Gomez-Andres, Francina Munell, Laura Costa-Comellas, Jana Haberlova, Marie Rohlenova, De Vos Elke, Jan L. De Bleecker, Cristina Dominguez-Gonzalez, Giorgio Tasca, Claudia Weiss, Nicolas Deconinck, Roberto Fernandez-Torron, Adolfo Lopez de Munain, Ana Camacho-Salas, Bela Melegh, Kinga Hadzsiev, Lea Leonardis, Blaz Koritnik, Matteo Garibaldi, Juan Carlos de Leon-Hernandez, Edoardo Malfatti, Arturo Fraga-Bau, Isabelle Richard, Isabel Illa, Jordi Diaz-Manera

BRAIN (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.